Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02153450 · ClinicalTrials.gov registry record · Early Phase 1
Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer
A Early Phase 1 study, sponsored by Case Comprehensive Cancer Center.
- Completed
- Registry status
- Early Phase 1
- Development phase
- 8
- Enrollment target
NCT02153450 is a Early Phase 1 study that has completed, run by Case Comprehensive Cancer Center. The registered enrollment target is 8 participants.
The verdict
NCT02153450, a Early Phase 1 study, has completed, sponsored by Case Comprehensive Cancer Center.
- COMPLETED
- Registry status
- Early Phase 1
- Development phase
- 8 participants
- Enrollment target
Study Summary
This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in treating patients with pancreatic cancer that may be removed (borderline-resectable) or not removed by surgery. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage to normal tissue. Metformin hydrochloride, used for diabetes, may also kill cancer cells as demonstrated in laboratory studies. Giving stereotactic radiosurgery with metformin hydrochloride may kill more tumor cells.
Interventions
- DRUG metformin hydrochloride
- RADIATION stereotactic radiosurgery
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 8 participants |
| Start Date | 2015-05-08 |
| Est. Completion | 2020-06-13 |
| Phase | Early Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02153450
The ClinicalTrials.gov registry entry for NCT02153450 describes a study currently listed as completed, categorized as Early Phase 1. The registered enrollment target is 8 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Case Comprehensive Cancer Center, which has 407 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which metformin hydrochloride is the first listed.
NCT02153450 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02153450 about?
NCT02153450 is a clinical study titled "Stereotactic Radiosurgery and Metformin in Patients With Borderline-Resectable or Locally-Advanced Pancreatic Cancer". This pilot clinical trial studies stereotactic radiosurgery and metformin hydrochloride in treating patients with pancreatic cancer that may be removed (borderline-resectable) or not removed by surgery. Stereotactic radiosurgery may be able to send x-rays directly to the tumor and cause less damage ...
What is the current status of trial NCT02153450?
This trial is currently completed. It is a Early Phase 1 study. The enrollment target is 8 participants. The study started on 2015-05-08. Estimated completion is 2020-06-13.
What interventions are being tested in trial NCT02153450?
The interventions under investigation include: metformin hydrochloride (DRUG), stereotactic radiosurgery (RADIATION).
Who is sponsoring clinical trial NCT02153450?
This trial is sponsored by Case Comprehensive Cancer Center, which has 407 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.